Addus HomeCare (ADUS)
(Delayed Data from NSDQ)
$96.62 USD
-0.37 (-0.38%)
Updated Apr 17, 2024 04:00 PM ET
After-Market: $96.49 -0.13 (-0.13%) 5:34 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ADUS 96.62 -0.37(-0.38%)
Will ADUS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ADUS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADUS
Elevance Health (ELV), CD&R to Unveil Primary Care Offering
Are Medical Stocks Lagging HCA Healthcare (HCA) This Year?
ADUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
ADUS vs. USPH: Which Stock Should Value Investors Buy Now?
Acadia (ACHC) Buys CTCs to Boost Care Access in North Carolina
Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?
Other News for ADUS
Commit To Buy Addus HomeCare At $55, Earn 12.8% Annualized Using Options
Homecare Homebase Announces April 2024 Gold Standard Award Winner
ADUS: A Home Health Care Provider With Solid Growth
Addus HomeCare price target raised by $5 at Stephens, here's why
Addus HomeCare: A Home Health Care Provider With Solid Growth